MediWound Ltd. (NASDAQ:MDWD) Receives Average Rating of “Hold” from Brokerages

MediWound Ltd. (NASDAQ:MDWD) has received an average recommendation of “Hold” from the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $33.00.

MDWD has been the topic of several research analyst reports. Wall Street Zen cut MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Weiss Ratings cut shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th.

Insider Buying and Selling

In other MediWound news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MDWD. UBS Group AG boosted its position in shares of MediWound by 90.1% during the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after purchasing an additional 68,756 shares in the last quarter. Silverberg Bernstein Capital Management LLC raised its holdings in MediWound by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock worth $3,222,000 after purchasing an additional 16,081 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its position in MediWound by 22.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 71,000 shares of the biopharmaceutical company’s stock valued at $1,311,000 after buying an additional 13,196 shares during the period. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Stock Performance

Shares of NASDAQ MDWD traded up $0.05 during trading hours on Wednesday, hitting $13.52. The company’s stock had a trading volume of 12,461 shares, compared to its average volume of 94,720. MediWound has a 12 month low of $12.52 and a 12 month high of $20.03. The stock has a market cap of $173.73 million, a price-to-earnings ratio of -7.51 and a beta of 0.14. The business has a 50-day simple moving average of $13.80 and a 200-day simple moving average of $15.27.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The business had revenue of $3.09 million for the quarter, compared to the consensus estimate of $2.59 million. On average, equities research analysts forecast that MediWound will post -2.31 EPS for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative enzymatic therapies for tissue injury and wound care. The company’s products are designed to remove damaged or nonviable tissue while helping preserve healthy tissue, supporting wound management and healing.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based therapy used for the enzymatic removal of eschar in adults with deep partial-thickness and full-thickness thermal burns.